Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 5.02%

Arrowhead Pharmaceuticals reported an EPS of $0.22, which was significantly lower than expected, leading to a stock decline of 5.02%. The lack of revenue figures and management commentary adds uncertainty to the company's outlook. Investors may be concerned about the company's performance given the substantial EPS miss.